Related Experiment Video

Updated: Jul 10, 2026

Inducible and Reversible Dominant-negative (DN) Protein Inhibition
08:35

Inducible and Reversible Dominant-negative (DN) Protein Inhibition

Published on: January 7, 2019

Oligodeoxynucleotide decoy therapy blocks type 1 procollagen transcription and the prolyl hydroxylase beta subunit

Chun-Nam Lok1, H Paul Ehrlich, Sheryl L White

  • 1Department of Anatomy, Hong Kong University, Peoples' Republic of China.

Journal of Cellular Biochemistry
|November 22, 2007
PubMed

Insights

This study introduces a novel DNA decoy therapy to combat lung fibrosis caused by transforming growth factor-beta1 (TGF-beta1). The therapy silences collagen gene expression, offering a new approach to treating fibrotic lung diseases.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Biochemistry

Background:

  • Persistent transforming growth factor-beta1 (TGF-beta1) exposure in lungs drives type 1 collagen synthesis, leading to fibrosis, morbidity, and mortality.
  • Current therapeutic strategies for lung fibrosis remain limited.

Purpose of the Study:

  • To investigate a novel double-stranded (ds) DNA decoy therapy targeting COL1A1 gene expression in human embryonic lung fibroblasts.
  • To determine the efficacy of dsDNA decoy therapy in inhibiting type 1 collagen synthesis at both transcriptional and translational levels.

Main Methods:

  • Utilized human embryonic lung fibroblasts exposed to TGF-beta1.
  • Administered a novel dsDNA decoy with phosphorothioate (PT) linkages containing the TGF-beta cis-element from the COL1A1 gene promoter.
  • Employed comparative proteomics to analyze protein level changes, specifically focusing on disulfide isomerase and the prolyl-4-hydroxylase (P-4-H) beta subunit.

Main Results:

  • The dsDNA decoy effectively silenced COL1A1 gene expression in the presence of TGF-beta1.
  • Comparative proteomics revealed that dsDNA decoy therapy increased the levels of disulfide isomerase and the P-4-H beta subunit.
  • These results indicate inhibition of type 1 collagen synthesis at both transcriptional and translational levels.

Conclusions:

  • The novel dsDNA decoy therapy demonstrates potential in inhibiting type 1 collagen synthesis, offering a dual-level inhibitory mechanism.
  • This therapeutic approach may represent a promising strategy for managing and treating lung fibrosis.
  • Further research is warranted to explore the clinical applicability of this dsDNA decoy therapy.

Related Concept Videos

Types of RNA01:20

Types of RNA

Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
Types of RNA01:23

Types of RNA

Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...